Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  MnrjSpVv[3Srb36gRZN{[Xl? NF\HXmIxNjVxMT:yMlUh|ryP Mle0N{Bp M4fpXJJm\HWlZYOgeIhmKGKjc3HsJGNDKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGfJXlUzPjB7N{i3Ny=>
T24 BC  NHTXXI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;EfFAvPS9zL{KuOUDPxE1? MonENlQhcA>? MW\lcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>? MUKyOlA6Pzh5Mx?=
T24 BC  MX\BdI9xfG:|aYOgRZN{e2G7 NHTrRXQzNjVizszN NH6zXJozPCCq M1vKUJNmdnOrdHn6[ZMhSkNiY3XscJMhfG9ic3;yZYZmdmmkLXnu[JVk\WRiYYDvdJRwfGmlwrC= MlTONlYxQTd6N{O=
HepG2 NHHCOotHfW6ldHnvckBCe3OjeR?= Ml\mNlDDqM7:TR?= MmnoNlTDqGh? M1TScpBzd2S3Y3XzJIFvKGmwdHXud4Uh[3m2b4DsZZNucWNidnHjeY9tcXqjdHnvckBkd3K{ZYPwc45lcW6pIITvJIEhdm:2YXLs[UBlcWyjdHH0bY9vKG:oIITo[UBGWiClaYP0[ZJvew>? NIfM[W8zPTl|NEKzNi=>
U-87 MG  MmfVSpVv[3Srb36gRZN{[Xl? M2\SV|IxyqEQvF2= NGrUbY0zPMLiaB?= M2f0c4lv[3KnYYPld{Bld3WkbHWtcYVu[nKjbnWgZo92dmRic4TyeYN1fXKncx?= NH7PbZMzPTl|NEKzNi=>
HepG2 MYPGeY5kfGmxbjDBd5NigQ>? NWrvUWFQOjEEoN88US=> NUjET3lsPi9{NDDo NELhWY9qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? NHWyNnEzPTl|NEKzNi=>
U-87 MG  MnjkSpVv[3Srb36gRZN{[Xl? NWrsd21bOjEEoN88US=> M3;Z[VYwOjRiaB?= MYTpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCOQ{OtTWkh[2:2cnXheIVlKHerdHigR3E> Mm[zNlU6OzR{M{K=
HepG2 M4DXU2Z2dmO2aX;uJGF{e2G7 M2nFW|IxyqEQvF2= NG[0PIg3NzJ2IHi= NYDxUotQ\GWlcnXhd4V{KEyFMz3JTUBl\We{YXTheIlwdsLiZoLvcUA3KGh? M3nZXlI2QTN2MkOy
U-87 MG  NFfHV4VHfW6ldHnvckBCe3OjeR?= M4PWRVIxyqEQvF2= MXO2M|I1KGh? M2LIS4lv[3KnYYPld{B1cGViYYX0c5Bp[WerYzDmcJV5KCCjdDC2JIghf2irbHWgbY5pcWKrdIOgeIhqeyCobIX4JIF1KDJ2aB?= NV3MXlhEOjV7M{SyN|I>
HepG2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\BS24zOC92MDFOwG0> NGrqOJQzPC92ODDo M1LOVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NWLk[5lxOjV7M{SyN|I>
U-87 MG  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSyNE81OCEQvF2= NWjhVGdmOjRxNEigbC=> NIHDTHdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYPUTJFlOjV7M{SyN|I>
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTCT5pjOC5|LUGwJO69VQ>? NV\rXmlyOjRxN{KgbC=> NGLJWW5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NIHGe2czPTZ7N{i5PS=>
H460 M3uyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLZNE4{NTFyIN88US=> M3fNWVI1Nzd{IHi= MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVeyOVY6Pzh7OR?=
A549 NV\kPYJiSXCxcITvd4l{KEG|c4PhfS=> NX3LcIFsOS9|IN88US=> NX\nWVViPDhiaB?= NFf2cmRqdmS3Y3XzJIFxd3C2b4Ppdy=> M4q4c|I2Pjl5OEm5
H460 NHnYWIJCeG:ydH;zbZMhSXO|c3H5 MYCxM|Mh|ryP M2LHflQ5KGh? NEHuOYhqdmS3Y3XzJIFxd3C2b4Ppdy=> NWntdHdvOjV4OUe4PVk>
A549 MVLGeY5kfGmxbjDBd5NigQ>? NW\N[5ZMOyEQvF2= NV7nfIdzQCCq M4r3d4Jtd2OtczDBT3Qh[WO2aY\heIlwdg>? MnO1NlU3QTd6OUm=
H460 MlHqSpVv[3Srb36gRZN{[Xl? MlH1N{DPxE1? NIGycoc5KGh? NWTP[mVY[myxY3vzJGFMXCCjY4TpeoF1cW:w MWKyOVY6Pzh7OR?=
A549 MVfGeY5kfGmxbjDBd5NigQ>? Mli4N{DPxE1? NX\yRVJsQCCq MXLicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ? M3jqZlI2Pjl5OEm5
H460 NIDxc2xHfW6ldHnvckBCe3OjeR?= MkGzN{DPxE1? NWPhVm1ZQCCq M1fISIJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= NF\nNWEzPTZ7N{i5PS=>
RMG1 NUnTeHFXS2WubDDWbYFjcWyrdImgRZN{[Xl? MUixMVMxKM7:TR?= MXq3NkBp MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVOyOVUyQTF2OB?=
RMG2 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnnZNU0{OCEQvF2= NV7IVXZRPzJiaB?= MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1rhV|I2PTF7MUS4
KOC7C NUmxTIRGS2WubDDWbYFjcWyrdImgRZN{[Xl? MnnQNU0{OCEQvF2= NX3FSGl3PzJiaB?= NEX2UWZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3Psb|I2PTF7MUS4
HAC2 M4nPNWNmdGxiVnnhZoltcXS7IFHzd4F6 MnvzNU0{OCEQvF2= NESzcHc4OiCq NYHXdFRp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy Mn32NlU2OTlzNEi=
RMG2 M1HTOmNmdGxiVnnhZoltcXS7IFHzd4F6 MmHyNU0{OCEQvF2= MXe0PEBp NF\vbppl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MVSyOVUyQTF2OB?=
OVISE NUDYdZRrS2WubDDWbYFjcWyrdImgRZN{[Xl? Mo\wNU0{OCEQvF2= MoPwOFghcA>? MYDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXXROGpwOjV3MUmxOFg>
SKOV3 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M33iR|EuOzBizszN NG\hWFk1QCCq NVPHbHNx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NI\5NYUzPTVzOUG0PC=>
A2780 MoXSR4VtdCCYaXHibYxqfHliQYPzZZk> NXjzbIR3OS1|MDFOwG0> NGezRZM1QCCq MnnE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NELvXIgzPTVzOUG0PC=>
RMG1 MXrBdI9xfG:|aYOgRZN{e2G7 MYmzNEDPxE1? M2XzV|I1KGh? NHPxfXVqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn\PNlU2OTlzNEi=
RMG2 MWnBdI9xfG:|aYOgRZN{e2G7 NI\ZSpg{OCEQvF2= NV7qfGhzOjRiaB?= NVPsfHpHcW6mdXPld{BieG:ydH;zbZM> MVKyOVUyQTF2OB?=
HCC1806 NVTuOldLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqzbWQxNTFyIN88US=> NFHmcGY1QCCq M{fzNmVEPTB;Mj64OQKBkcLz4pEJNE4xPyEQvF2= NXe4SpJ3OjV{OUO1O|Y>
MDA-MB-231  NYPHUnlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PMUVAuOTBizszN Mme4OFghcA>? M1j0V2VEPTB;MT6xN-KBkcLz4pEJNE4xPyEQvF2= M3K0fVI2Ojl|NUe2
GL-1 NHiwZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzud5l6OC5z4pETNVAx6oDLzszN M4XDTlQ5KGh? NIi3bJpKSzVyPUmuPVEh|ryP M33USFI1QDhzNUC4
CLBL-1 M{HCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHeVAvOeLCk{GwNQKBkc7:TR?= NVfNUpZ3PDhiaB?= M2jabWlEPTB;M{OuNEDPxE1? NWLMWVZTOjR6OEG1NFg>
UL-1 NWnKTmQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\OVFAvOeLCk{GwNQKBkc7:TR?= MWi0PEBp MV\JR|UxRTdwMEGg{txO MY[yOFg5OTVyOB?=
Ema NELQW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;JSo0xNjIkgKOxNFDjiIoQvF2= MXi0PEBp NXzMVFZbUUN3ME21PE44KM7:TR?= M3ntelI1QDhzNUC4
PANC-1 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Z[WFEOC1{NTFOwG0> MYq3NkBp Ml[xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{jwXVI1PTF7N{Wx
MIA M1j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTNNE0zPSEQvF2= NGP0V2o4OiCq M2TJU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmDsNlQ2OTl5NUG=
AsPC-1 M{HhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULoU4dzOC1{NTFOwG0> NHLsSG44OiCq M1[4eYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkXDNlQ2OTl5NUG=
PANC-1 NF\pe2VHfW6ldHnvckBCe3OjeR?= MVKwMlUh|ryP MVuyOEBp NUTEO|M1cW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi MXKyOFUyQTd3MR?=
MIA NHXM[|lHfW6ldHnvckBCe3OjeR?= Mk\ENE42KM7:TR?= Ml3VNlQhcA>? M3XzZYlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? M{W3cFI1PTF7N{Wx
AsPC-1 M1TYVmZ2dmO2aX;uJGF{e2G7 M3rN[FAvPSEQvF2= Mo\TNlQhcA>? MUTpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NGiyRVEzPDVzOUe1NS=>
U87MG NWDke5VHS2WubDDWbYFjcWyrdImgRZN{[Xl? M2rTZVAuOjVizszN NFXycFIzPC17NjDo M1vxdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MonINlQxPjV3MkK=
SGC7901  MkP4SpVv[3Srb36gRZN{[Xl? NVTtPVdpOC55NT:xNOKh|ryP M{XPTFQ5KGh? M1TLTYRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=> M2ryS|I{QTF{MkS2
MGC803  NEG3TJlHfW6ldHnvckBCe3OjeR?= NIf6[VAxNjd3L{GwxsDPxE1? M2r6XFQ5yqCq NGDSRpll\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA> MoXuNlM6OTJ{NE[=
TykNu NHflelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3HRmt{UUN3ME2zMlUh|ryP NEPTZ2IzOzh5N{CxNi=>
TykNuR NFK3b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXFXm01UUN3ME21MlUh|ryP M2PVPVI{QDd5MEGy
M41 NEPq[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvUbJJKSzVyPUK0Mlch|ryP MljFNlM5PzdyMUK=
M41R Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrrTWM2OD1zOT64JO69VQ>? MXyyN|g4PzBzMh?=
OVCAR8 M17NZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDqTWM2OD1|MT6xJO69VQ>? NHz3UWszOzh5N{CxNi=>
HeyA8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ2LkOg{txO NHXMPXAzOzh5N{CxNi=>
A2780CP MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\qVGlEPTB;Nz62JO69VQ>? MVqyN|g4PzBzMh?=
OVCAR5 NYq1eWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvpWmRHUUN3ME22Mlch|ryP Mn21NlM5PzdyMUK=
A2780S MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKyTWM2OD1zND61JO69VQ>? MWKyN|g4PzBzMh?=
MCAS NGLUclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF{LkWg{txO MXOyN|g4PzBzMh?=
NCI-H727 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYDVRpp6OC1zMECg{txO MYqyOE84OiCq MXvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NWPOZndEOjJ2OUm0N|c>
GOT1 M2XmdWNmdGxiVnnhZoltcXS7IFHzd4F6 M1;qTlAuOTByIN88US=> NVHOTWJiOjRxN{KgbC=> NIr2ephl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWqyNlQ6QTR|Nx?=
BON1 Ml7OR4VtdCCYaXHibYxqfHliQYPzZZk> Mn3mNE0yODBizszN M3fZNFI1Nzd{IHi= NVrCUFZw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MXWyNlQ6QTR|Nx?=
BON1 NILWNHJCeG:ydH;zbZMhSXO|c3H5 M2r6VlAuOTBizszN M{jCXlI1KGh? NVXxdYF4cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M4fPZ|IzPDl7NEO3
BON1 M1;QZ2Z2dmO2aX;uJGF{e2G7 NYLuNlhoPy53L{GwJO69VQ>? M4XIOVghcA>? NIm5XnFl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhfGinIHHueIku[XCxcITveIlkKHC{b4TlbY5{KEKFTEKgZY5lKEKlbD3YUC=> NEnTSoczOjR7OUSzOy=>
Kasumi-1 NInXUXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4jKelAuOjBizszN MoDmNlQwPDhiaB?= MnTr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MnzkNlI1ODd{Mki=
HL-60 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlHvNE0zOCEQvF2= NEf6[pMzPC92ODDo NXPkN5RX\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MV6yNlQxPzJ{OB?=
Kasumi-1 MY\BdI9xfG:|aYOgRZN{e2G7 MWKxNEDPxE1? NITkS2wzPCCq MY\pcoR2[2W|IHHwc5B1d3Orcx?= NVjHNJpxOjJ2MEeyNlg>
HL-60 Mm\KRZBweHSxc3nzJGF{e3OjeR?= M2LYU|ExKM7:TR?= NXrMcVVyOjRiaB?= NW\De4ZRcW6mdXPld{BieG:ydH;zbZM> MmS3NlI1ODd{Mki=
Kasumi-1 MnnWSpVv[3Srb36gRZN{[Xl? M3rQc|IvPS93L{GwJO69VQ>? NYTp[3lSOjRiaB?= M4HOdoRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? MXOyNlQxPzJ{OB?=
HL-60 MVzGeY5kfGmxbjDBd5NigQ>? M3XheFIvPS93L{GwJO69VQ>? NGHPNlAzPCCq NVfobHVi\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 NYG5XYl2OjJ2MEeyNlg>
Kasumi-1 MmfHSpVv[3Srb36gRZN{[Xl? NYOwcIV1Oi53L{WvNVAh|ryP NGTBe5QzPCCq MUHpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NWKzd|MzOjJ2MEeyNlg>
HL-60 MnPySpVv[3Srb36gRZN{[Xl? M2jwWlIvPS93L{GwJO69VQ>? MYWyOEBp MVfpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MVuyNlQxPzJ{OB?=
K562 M4PjSWZ2dmO2aX;uJGF{e2G7 Mm\MNlAh|ryP M1HwfFQ5KGh? NF7LT|NqdmS3Y3XzJIF2fG:yaHHnfeKh NXHuc4prOjJ2MEeyNlg>
OCUT1 NGjZeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXVNE4yNTNizszN MYK1JIQ> NGnEUZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFvCOJIzOjB7MEK3NS=>
K1 NHO1fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfvNE4yNTNizszN MkLuOUBl MmPJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NWrIWlRLOjJyOUCyO|E>
OCUT1 M3zJXGZ2dmO2aX;uJGF{e2G7 MWezJO69dQ>? M4\DeVI1KGh? M1LsOINifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V? MUKyNlA6ODJ5MR?=
CaOV3 MmPSR4VtdCCYaXHibYxqfHliQYPzZZk> MYixM|UwOTBizszN Mlu5OFghcA>? NGTsXGtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYKgZ491emWjdHXkJJdqfGhicHHjcIl1[XinbB?= MVOyNVc4PTB3NB?=
SKOV3 NE\U[IVEgXSxdH;4bYNqfHliQYPzZZk> NEe1em42KM7:TR?= NISxRpM1QCCq NUPyV5Ru\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MWqyNVc4PTB3NB?=
A2780 MmXVR5l1d3SxeHnjbZR6KEG|c3H5 MoLkOUDPxE1? M1\LdVQ5KGh? NHHXellmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh M3TnUlIyPzd3MEW0
HT-29  M3vyeGN6fG:2b4jpZ4l1gSCDc4PhfS=> M1vlelUh|ryP M3XLXlQ5KGh? NYD0UXAy\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NEHldIUzOTd5NUC1OC=>
A498 M1OxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMVQxKM7:TR?= MkjtO|IhcA>? M4jNRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXnL[JNKOjF4NESwOVA>
CAKI-1 M3m5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqwMVQxKM7:TR?= NULvcYt{PzJiaB?= MXjJR|UxhjFyIN88US=> MVWyNVY1PDB3MB?=
769-P MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmwMVQxKM7:TR?= NUfjOmRZPzJiaB?= M{Xoc2lEPTC-NT2xNEDPxE1? NV\W[|JKOjF4NESwOVA>
786-0 MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrCWY8xNTRyIN88US=> MnHyO|IhcA>? MYPJR|UxhjVizszN NH\hVHIzOTZ2NEC1NC=>
786-O MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;WTFAuOjBizszN NEXMV3Y4OiCq MkfFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M2fPfVIyPjR2MEWw
CAKI-1 NE\BcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn4OlcxNTJyIN88US=> NEHsZmg4OiCq Mlf2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3PZPFIyPjR2MEWw
769-P MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjwNE0zOCEQvF2= NYn2XXEzPzJiaB?= MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NEjjNWEzOTZ2NEC1NC=>
A498 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMVIxKM7:TR?= NELF[pE4OiCq MlXjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1LMPFIyPjR2MEWw
CWR22RV1 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGnlOXgyOCEQvF2= MV2yOEBp M4PxRYlv[3KnYYPld{B{\W6|aYTpeol1gSCxZjDoeY1idiCFV2KyNnJXOSClZXzsd{B1dyC{YXTpZZRqd25? M2OyVlIyPDl4Mkez
CWR22RV1 NXzYNpZpSXCxcITvd4l{KEG|c4PhfS=> NFfSemwyOCEQvF2= NIL1UZMzPCCq M{LHdoVvcGGwY3XzJJJi\GmjdHnvckBqdmS3Y3XkJIFxd3C2b4Ppdy=> NHi3SnMzOTR7NkK3Ny=>
CWR22RV1 M1HP[WZ2dmO2aX;uJGF{e2G7 MUi1JO69VQ>? MXGyOEBp MWjy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?= M2XGflIyPDl4Mkez
HepG2  Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6zfIw2NzFyL{KwM|QxKM7:TR?= M2TFRVI1NzR6L{eyJIg> NIjsbZVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX[ydlNJOjB6NEK0NlU>
Bel-7402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrn[mY2NzFyL{KwM|QxKM7:TR?= MmX3NlQwPDhxN{KgbC=> M3HncIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3;aSlIxQDR{NEK1
HepG2  MV;GeY5kfGmxbjDBd5NigQ>? NF;KeoY2NzFyL{KwJO69VQ>? NIDqfmozPCCq MnfndoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn NV\Jd|RZOjB6NEK0NlU>
Bel-7402 MlzwSpVv[3Srb36gRZN{[Xl? M{C2elUwOTBxMkCg{txO MVqyOEBp NFHjWpNz\XO3bITzJIlvKHSqZTDhZ4N2dXWuYYTpc44hd2ZiY3XscEBvfW2kZYKgbY4hfGinIFeyM20heGijc3W= NGiwTY8zODh2MkSyOS=>
HepG2  MmH5RZBweHSxc3nzJGF{e3OjeR?= NUnreHJzPS9zMD:yNEDPxE1? NEDZdW0zPC92ODDo NILOT2NqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl MorsNlA5PDJ2MkW=
Bel-7402 NYr4PZltSXCxcITvd4l{KEG|c4PhfS=> NH76NGo2NzFyL{KwJO69VQ>? M3Gy[|I1NzR6IHi= NVXLSXA2cW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> NYjLSIk5OjB6NEK0NlU>
OAW-42 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMVQxKM7:TR?= MlHCO|LDqGh? NVjsOGRpUUN3MI6xNEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXnlUWNnOjB2MEWyPVY>
PA-1  MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiwMVQxKM7:TR?= MXW3NuKhcA>? M1K2PGlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFjVOG4zODRyNUK5Oi=>
SKOV3  MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTObIMxNTRyIN88US=> NHrVe2s4OsLiaB?= MXfJR|UxhjNyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUHi[FlWOjB2MEWyPVY>
A2780 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3ZNE0zOCEQvF2= MmHkOFgwPzJiaB?= M4nj[WlEPTEEoE5CpFPDqM7:bR?= MmnyNlA1ODV{OU[=
A2780cis  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[3NE0zOCEQvF2= NXznXHhGPDhxN{KgbC=> NFLu[GdKSzVywrC9xsA3yqEQvH2= MoPYNlA1ODV{OU[=
SKW6.4 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XiZlIuOTEEoN88US=> NH7MPFU1QMLiaB?= M{DENYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFnRSGkzODF|MEm2NC=>
MAVER NFjRVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHIeG5XOi1zMNMg{txO NUOwRnRWPDkEoHi= NFTnWGFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoqzNlAyOzB7NkC=
BJAB NEPJfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj1WmhiOi1zMNMg{txO NEnIdXE1QMLiaB?= NVO3bWNGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{DCRlIxOTNyOU[w
OCI M17PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GzVVIuOTEEoN88US=> MX[0POKhcA>? NHm4eI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{ezelIxOTNyOU[w
MOLM M13heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5Nk0yOMLizszN NFG0PVQ1QMLiaB?= MmDtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MWOyNFE{ODl4MB?=
HL-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[yMVExyqEQvF2= NEewVZI1QMLiaB?= NIHSeJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mm\GNlAyOzB7NkC=
SKW6.4 NGLrOGtCeG:ydH;zbZMhSXO|c3H5 NYTMW2R[OTEEoN88US=> NVPDNYVYOjRxNEigbC=> M2Lr[4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M3XWdlIxOTNyOU[w
MAVER NETFeW5CeG:ydH;zbZMhSXO|c3H5 M1zCdVExyqEQvF2= M{K0cVI1NzR6IHi= NUi3TWF6cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NWfEWWlUOjBzM{C5OlA>
BJAB MlHXRZBweHSxc3nzJGF{e3OjeR?= NYKzS2U3OTEEoN88US=> M4raSFI1NzR6IHi= MlTpbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MYKyNFE{ODl4MB?=
OCI MV7BdI9xfG:|aYOgRZN{e2G7 NGTzRYwyOMLizszN MWCyOE81QCCq NH[1ZZhqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NYDIfmpoOjBzM{C5OlA>
MOLM NFvUfZNCeG:ydH;zbZMhSXO|c3H5 NXnIOmFPOTEEoN88US=> MXOyOE81QCCq NWC0VVB4cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NH61OYozODF|MEm2NC=>
HL-60 Mn32RZBweHSxc3nzJGF{e3OjeR?= M1TnOFExyqEQvF2= MYKyOE81QCCq MojYbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= MWCyNFE{ODl4MB?=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID